Maren Reimer1, Stephanie M Helfert, Ralf Baron. 1. Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital, Kiel, Germany *Maren Reimer and Stephanie M. Helfert contributed equally to the writing of this article.
Abstract
PURPOSE OF REVIEW: The sensory phenotype can be used as a surrogate marker of underlying mechanisms of pain generation and is assessed by tools like the Quantitative Sensory Testing, Patient Reported Outcomes or the Capsaicin Response Test. In order to establish an individualized, mechanism-based treatment of pain, it has to be demonstrated that subgroups of patients with a distinct sensory phenotype respond differently to a certain treatment. RECENT FINDINGS: Retrospective analyses of several clinical trials revealed that the presence of certain somatosensory abnormalities in the painful area was associated with a better treatment outcome. Examples will be discussed in this article, showing that somatosensory phenotyping of patients with neuropathic pain is a promising method to subgroup patients in order to predict their response to treatment. SUMMARY: The discussed trials show the importance of the development of an individualized pain therapy. Up to now, no clinical trial has prospectively used the sensory phenotype as an inclusion or stratification criterion. Academic researchers and pharmaceutical industry should be encouraged to implement this approach in future trial designs.
PURPOSE OF REVIEW: The sensory phenotype can be used as a surrogate marker of underlying mechanisms of pain generation and is assessed by tools like the Quantitative Sensory Testing, Patient Reported Outcomes or the Capsaicin Response Test. In order to establish an individualized, mechanism-based treatment of pain, it has to be demonstrated that subgroups of patients with a distinct sensory phenotype respond differently to a certain treatment. RECENT FINDINGS: Retrospective analyses of several clinical trials revealed that the presence of certain somatosensory abnormalities in the painful area was associated with a better treatment outcome. Examples will be discussed in this article, showing that somatosensory phenotyping of patients with neuropathic pain is a promising method to subgroup patients in order to predict their response to treatment. SUMMARY: The discussed trials show the importance of the development of an individualized pain therapy. Up to now, no clinical trial has prospectively used the sensory phenotype as an inclusion or stratification criterion. Academic researchers and pharmaceutical industry should be encouraged to implement this approach in future trial designs.
Authors: Peter A W Rogers; G David Adamson; Moamar Al-Jefout; Christian M Becker; Thomas M D'Hooghe; Gerard A J Dunselman; Asgerally Fazleabas; Linda C Giudice; Andrew W Horne; M Louise Hull; Lone Hummelshoj; Stacey A Missmer; Grant W Montgomery; Pamela Stratton; Robert N Taylor; Luk Rombauts; Philippa T Saunders; Katy Vincent; Krina T Zondervan Journal: Reprod Sci Date: 2016-09-27 Impact factor: 3.060
Authors: Jan Rosner; Robin Lütolf; Pascal Hostettler; Michael Villiger; Ron Clijsen; Erich Hohenauer; Marco Barbero; Armin Curt; Michèle Hubli Journal: Spinal Cord Date: 2021-02-16 Impact factor: 2.772
Authors: Robert R Edwards; Robert H Dworkin; Dennis C Turk; Martin S Angst; Raymond Dionne; Roy Freeman; Per Hansson; Simon Haroutounian; Lars Arendt-Nielsen; Nadine Attal; Ralf Baron; Joanna Brell; Shay Bujanover; Laurie B Burke; Daniel Carr; Amy S Chappell; Penney Cowan; Mila Etropolski; Roger B Fillingim; Jennifer S Gewandter; Nathaniel P Katz; Ernest A Kopecky; John D Markman; George Nomikos; Linda Porter; Bob A Rappaport; Andrew S C Rice; Joseph M Scavone; Joachim Scholz; Lee S Simon; Shannon M Smith; Jeffrey Tobias; Tina Tockarshewsky; Christine Veasley; Mark Versavel; Ajay D Wasan; Warren Wen; David Yarnitsky Journal: Pain Date: 2016-09 Impact factor: 7.926
Authors: Lucy H R Whitaker; Jen Reid; Alex Choa; Stuart McFee; Marta Seretny; John Wilson; Rob A Elton; Katy Vincent; Andrew W Horne Journal: PLoS One Date: 2016-04-05 Impact factor: 3.240